Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

20011,223 citationsJournal Article

Authors

Alan N. Gordon · Aberdeen Royal Infirmary

John Fleagle · Aberdeen Royal Infirmary

David Guthrie · Aberdeen Royal Infirmary

David E. Parkin · Aberdeen Royal Infirmary

Martin Gore · Aberdeen Royal Infirmary

Ángel J. Lacave · Aberdeen Royal Infirmary

Abstract

The comparable efficacy, favorable safety profile, and convenient dosing support the role of PLD as a valuable treatment option in this patient population.

Topics & Keywords

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 19, Issue 14, pp. 3312-3322

DOI: 10.1200/jco.2001.19.14.3312

Field-Weighted Citation Impact: 72.48